Dr. Rama Jasty
Claim this profileC S Mott Children's Hospital
Studies Tumors
Studies Cancer
11 reported clinical trials
28 drugs studied
Area of expertise
1Tumors
Stage I
Stage IV
Stage II
2Cancer
Stage I
Stage II
Stage IV
Affiliated Hospitals
Clinical Trials Rama Jasty is currently running
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
Chemotherapy
for Wilms Tumor
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).
Recruiting1 award Phase 212 criteria
More about Rama Jasty
Clinical Trial Related6 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Rama Jasty has experience with
- Cyclophosphamide
- Dactinomycin
- Carboplatin
- Etoposide
- Questionnaire Administration
- Vincristine
Breakdown of trials Rama Jasty has run
Tumors
Cancer
Rhabdomyosarcoma
Alveolar Rhabdomyosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rama Jasty specialize in?
Rama Jasty focuses on Tumors and Cancer. In particular, much of their work with Tumors has involved Stage I patients, or patients who are Stage IV.
Is Rama Jasty currently recruiting for clinical trials?
Yes, Rama Jasty is currently recruiting for 4 clinical trials in Ann Arbor Michigan. If you're interested in participating, you should apply.
Are there any treatments that Rama Jasty has studied deeply?
Yes, Rama Jasty has studied treatments such as Cyclophosphamide, Dactinomycin, Carboplatin.
What is the best way to schedule an appointment with Rama Jasty?
Apply for one of the trials that Rama Jasty is conducting.
What is the office address of Rama Jasty?
The office of Rama Jasty is located at: C S Mott Children's Hospital, Ann Arbor, Michigan 48109 United States. This is the address for their practice at the C S Mott Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.